14331-27-2

Basic information

• Product Name: N'-acetylbenzohydrazide
• Synonyms: N'-acetylbenzohydrazide
• CAS NO: 14331-27-2
• Molecular Formula: C₉H₁₀N₂O₂
• Molecular Weight: 178.1879
• Mol File: 14331-27-2.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N'-acetylbenzohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: N'-acetylbenzohydrazide(14331-27-2)
• EPA Substance Registry System: N'-acetylbenzohydrazide(14331-27-2)

Safety Data

• Hazardous Substances Data: 14331-27-2(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 31, p. 805, 1994 DOI: 10.1002/jhet.5570310419

Upstream product

• 141-30-0 3,6-dichlorpyridazine 
• 613-94-5 benzoic acid hydrazide 
• 830-03-5 4-nitrophenol acetate 
• 64-19-7 acetic acid 
• 7647-01-0 hydrogenchloride 
• 101568-88-1 acetyl-benzoyl-isopropylidene-hydrazine 
• 41394-05-2 metamitron 
• 75-36-5 acetyl chloride 
• 13153-01-0 1-benzoyl-4-phenyl-3-thiosemicarbazide 
• 108-24-7 acetic anhydride 
• 98-88-4 benzoyl chloride 
• 1068-57-1 acetic acid hydrazide 
• 60-29-7 diethyl ether 
• 64-17-5 ethanol 

Downstream Products

• 101291-74-1 2-phenyl-5-(2-phenylethenyl)-1,3,4-thiadiazole 
• 1024613-86-2 cyclohexyl(5-phenyl-1,3,4-oxadiazol-2-yl)amine 
• 1391062-83-1 N-tert-butyl-5-phenyl-1,3,4-oxadiazol-2-amine 
• 486-38-4 1,2-dimethyl-5-phenyl-1,2-dihydro-pyrazol-3-one 
• 160455-80-1 4-benzyl-3-methyl-5-phenyl-4H-[1,2,4]triazole 
• 160455-78-7 4-allyl-3-methyl-5-phenyl-4H-1,2,4-triazole 
• 613-94-5 benzoic acid hydrazide 
• 64-19-7 acetic acid 
• 4046-03-1 2-methyl-5-phenyl-[1,3,4]oxadiazole 
• 725-12-2 2,5-bis-(phenyl)-1,3,4-oxadiazole 
• 138211-83-3 N'-acetyl-N,N'-dimethylbenzohydrazide 
• 126736-03-6 bistrimethylsilyl N₁-acetyl N₂-benzoylhydrazine 
• 59105-33-8 3-acetyl-5-phenyl-3H-[1,2,3,4]oxathiadiazole 2-oxide 
• 14929-23-8 3-methyl-4,5-diphenyl-4H-1,2,4-triazole 

Relevant articles and documents

1,2-Dibenzoyl- and 1-benzoyl-2-acetylhydrazines as reagents for recovering Cu(II) ions from alkaline solutions

The conditions of complexation of 1,2-diacylhydrazines (H2L) C6H5C(O)NHNHC(O)R, where R = C6H5 or CH3, with Cu(II) ions in alkaline solutions were studied. The composition of the complexes formed by precipitation of Cu(II) from alkaline solutions, (CuOH)2L and CuL, was determined. The possibility of afterpurification of solutions with a low Cu(II) content by pneumatic flotation using H2L was examined.

METAL COMPLEX, COMPOSITION AND LIGHT EMITTING DEVICE

A metal complex represented by formula (1) is provided. In formula (1), X represents a nitrogen atom or a group represented by ═C(RX)—; R1 represents an alkyl group having 4 or more carbon atoms; R2 represents an alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, monovalent heterocyclic, or substituted amino group or a halogen atom; rings A and B each independently represent an aromatic hydrocarbon ring or an aromatic heterocyclic ring; M represents a rhodium, palladium, iridium, or platinum atom; n1 represents an integer of 1 or more, n2 represents an integer of 0 or more, and n1+n2 is 2 or 3; A1-G1-A2 represents an anionic bidentate ligand; A1 and A2 each independently represent a carbon atom, an oxygen atom, or a nitrogen atom; and G1 represents a single bond or an atomic group constituting a bidentate ligand together with A1 and A2.

Synthesis of 1,3,4-oxadiazoles from 1,2-diacylhydrazines using [Et 2NSF2]BF4 as a practical cyclodehydration agent

The preparation of 1,3,4-oxadiazoles from 1,2-diacylhydrazines using XtalFluor-E ([Et2NSF2]BF4) as cyclodehydration reagent is described. Various functionalized 1,3,4-oxadiazoles were synthesized and it was found that the use of acetic acid as an additive generally improved the yields.

MAOS protocols for the general synthesis and lead optimization of 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines

General, high-yielding MAOS protocols for the expedient synthesis of functionalized 3,6-disubstituted-[1,2,4]triazolo[4,3-b]pyridazines are described amenable to an iterative analog library synthesis strategy for the lead optimization of an M1 antagonist